

# Debra L Richardson

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4307417/debra-l-richardson-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

40  
papers

1,605  
citations

17  
h-index

40  
g-index

44  
ext. papers

1,803  
ext. citations

2.2  
avg, IF

4.3  
L-index

#	Paper	IF	Citations
40	The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. <i>Gynecologic Oncology</i> , <b>2009</b> , 112, 55-9	4.9	536
39	Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. <i>Gynecologic Oncology</i> , <b>2015</b> , 136, 3-7	4.9	190
38	A detailed analysis of the learning curve: robotic hysterectomy and pelvic-aortic lymphadenectomy for endometrial cancer. <i>Gynecologic Oncology</i> , <b>2009</b> , 114, 162-7	4.9	121
37	Robotic hysterectomy and pelvic-aortic lymphadenectomy for endometrial cancer. <i>Obstetrics and Gynecology</i> , <b>2008</b> , 112, 1207-1213	4.9	102
36	Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer. <i>Gynecologic Oncology</i> , <b>2006</b> , 103, 667-72	4.9	71
35	Influence of intraoperative capsule rupture on outcomes in stage I epithelial ovarian cancer. <i>Obstetrics and Gynecology</i> , <b>2009</b> , 113, 11-17	4.9	69
34	Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. <i>Gynecologic Oncology</i> , <b>2008</b> , 111, 461-6	4.9	47
33	Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. <i>Gynecologic Oncology</i> , <b>2011</b> , 121, 269-72	4.9	46
32	Risk of Occult Uterine Sarcoma in Women Undergoing Hysterectomy for Benign Indications. <i>Obstetrics and Gynecology</i> , <b>2016</b> , 127, 468-473	4.9	42
31	Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2018</b> , 4, 196-202	13.4	40
30	Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , <b>2009</b> , 115, 396-400	4.9	36
29	A Phase II Trial of Stereotactic Ablative Radiation Therapy as a Boost for Locally Advanced Cervical Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2020</b> , 106, 464-471	4	35
28	Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?. <i>Gynecologic Oncology</i> , <b>2010</b> , 118, 47-51	4.9	34
27	Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin <sup>®</sup> ) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , <b>2017</b> , 146, 477-483	4.9	31
26	Malignant ovarian germ cell tumor - role of surgical staging and gonadal dysgenesis. <i>Gynecologic Oncology</i> , <b>2014</b> , 134, 84-9	4.9	29
25	Ovarian involvement in endometrioid adenocarcinoma of uterus. <i>Gynecologic Oncology</i> , <b>2015</b> , 138, 532-54.9	4.9	21
24	Paratubal borderline serous tumors. <i>Gynecologic Oncology</i> , <b>2009</b> , 113, 83-5	4.9	18

23	Local correction of extreme stomal prolapse following transverse loop colostomy. <i>Gynecologic Oncology</i> , <b>2008</b> , 111, 549-51	4.9	16
22	Robotic hysterectomy and lymphadenectomy for endometrial cancer: technical aspects and details of success-the Ohio State University method. <i>Journal of Robotic Surgery</i> , <b>2008</b> , 2, 71-6	2.9	12
21	Lymph node metastasis in endometrioid adenocarcinomas of the uterine corpus with occult cervical involvement. <i>Gynecologic Oncology</i> , <b>2012</b> , 127, 43-6	4.9	11
20	The prognostic significance of the triple negative phenotype in endometrial cancer. <i>Gynecologic Oncology</i> , <b>2010</b> , 118, 172-5	4.9	11
19	CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy. <i>Gynecologic Oncology</i> , <b>2008</b> , 111, 233-6	4.9	11
18	The prevalence of occult endometrial cancer in women undergoing hysterectomy for benign indications. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , <b>2018</b> , 223, 108-112	2.4	10
17	Robotic pelvic and aortic lymphadenectomy for endometrial cancer: the console surgeon's perspectives on surgical technique and directing the assistant. <i>Journal of Minimally Invasive Gynecology</i> , <b>2010</b> , 17, 180-5	2.2	9
16	Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>2009</b> , 19, 1195-8	3.5	8
15	Evolution of the Gynecologic Oncology Group protocols in the treatment of epithelial ovarian cancer. <i>Clinical Obstetrics and Gynecology</i> , <b>2012</b> , 55, 131-55	1.7	7
14	Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062). <i>Molecular Cancer Therapeutics</i> , <b>2020</b> , 19, 2363-2370	6.1	7
13	Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?. <i>International Journal of Gynecological Cancer</i> , <b>2013</b> , 23, 833-8	3.5	6
12	Panniculectomy concurrent with anterior pelvic exenteration for recurrent cervical cancer. <i>Gynecologic Oncology</i> , <b>2008</b> , 108, 449-51	4.9	6
11	Factors associated with clinical trial screening failures in gynecologic oncology. <i>Gynecologic Oncology</i> , <b>2014</b> , 134, 450-4	4.9	5
10	Metastatic squamous cell carcinoma of the vulva to the lung confirmed with allelotyping. <i>International Journal of Gynecological Pathology</i> , <b>2009</b> , 28, 497-501	3.2	4
9	Is there a high-risk subgroup of stage I epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy?. <i>International Journal of Gynecological Cancer</i> , <b>2010</b> , 20, 1125-31	3.5	4
8	Adnexal masses requiring surgical intervention in women with advanced cervical cancer. <i>Gynecologic Oncology</i> , <b>2014</b> , 134, 552-5	4.9	3
7	Correlation of cone biopsy with findings at radical hysterectomy and use of adjuvant radiation therapy. <i>Gynecologic Oncology</i> , <b>2012</b> , 124, 508-11	4.9	3
6	Isolated groin recurrence of vulvar cancer salvaged with multimodality therapy. <i>Gynecologic Oncology</i> , <b>2009</b> , 115, 306-7	4.9	2

- 5 Remote location interstitial brachytherapy with patient stabilization and subsequent transport to an outpatient center for treatment is safe and effective for the treatment of gynecologic malignancies. *Brachytherapy*, **2016**, 15, 341-346 2.4 1
- 4 Malignant Uterine Perivascular Epithelioid Cell Tumor: A Case Report. *Clinical Ovarian and Other Gynecologic Cancer*, **2012**, 5, 37-39
- 3 RE: Panniculectomy concurrent with anterior pelvic exenteration for recurrent cervical cancer. *Gynecologic Oncology*, **2008**, 110, 269 4.9
- 2 Recurrence patterns in patients with stage IIIC1 versus IIIC2 endometrial adenocarcinoma.. *Journal of Clinical Oncology*, **2012**, 30, e15501-e15501 2.2
- 1 Factors influencing primary treatment of midline vulvar cancers. *Gynecologic Oncology*, **2016**, 142, 133-138